PARTNERSHIP OPPORTUNITIES
Free Shipping in the U.S. for orders over $1000. Shop Now>>
Podoplanin, encoded by the PDPN gene, is a transmembrane glycoprotein located on chromosome 1p36.13. It consists of 162 amino acids and has a molecular weight of approximately 38–40 kDa. Post-translational modifications of podoplanin include phosphorylation and glycosylation, which can influence cellular localization, function, and interactions with other molecules. Podoplanin is primarily a membrane protein but can also be found in the cytoplasm and extracellular matrix.
Podoplanin is expressed in various tissues and cell types, including lymphatic endothelial cells, kidney podocytes, fibroblasts, and certain types of cancer cells. Various factors regulate its expression, including growth factors, cytokines, and transcription factors. The function of podoplanin varies depending on the tissue context, but it is primarily known for its involvement in lymphatic vessel development, maintenance, and metastasis.
In addition to being a lymphatic endothelial and mesothelial marker, podoplanin has been implicated in cancer progression and metastasis. High levels of podoplanin expression have been observed in numerous cancers, including squamous cell carcinoma, glioblastoma, and mesothelioma, where it is associated with tumor invasion, metastasis, and poor prognosis. Additionally, podoplanin expression has been linked to lymphangiogenesis, inflammation, and fibrosis in various pathological conditions. In this sense, podoplanin expression may serve as a diagnostic and prognostic marker in certain cancers, providing valuable information for patient management and personalized medicine approaches.
Regarding therapeutic targeting, one study created a cancer-specific monoclonal antibody (CasMab) targeting human podoplanin. Aberrantly glycosylated forms of podoplanin, including keratan sulfate or aberrant sialylation, found in LN229 glioblastoma cells were used to generate the antibody. The newly developed LpMab-2 antibody specifically recognized abnormal glycosylation patterns and a specific peptide sequence within podoplanin. Importantly, LpMab-2 demonstrated selective binding to cancer cells expressing podoplanin, as confirmed by flow cytometry and immunohistochemistry, while showing no reactivity with normal cells. These findings suggest that LpMab-2 holds promise as a molecular targeting agent for podoplanin-expressing cancers, potentially facilitating targeted therapy approaches against these malignancies.
NeoBiotechnologies offers a variety of antibodies against podoplanin that have been validated for ELISA, immunofluorescence, and immunohistochemistry, as well as HuProt validated options. Additionally, we hold exclusive rights to Podoplanin antibodies available for licensing or collaboration [https://www.neobiotechnologies.com/shop/?s=podoplanin].
Podoplanin, Aggrus, Glycoprotein 36, PA2.26 antigen, T1-alpha, Aggrus; Glycoprotein 36 KD; Glycoprotein 36; gp36; GP38; GP40; HT1A1; hT1alpha1; hT1alpha2; Lung type I cell membrane associated glycoprotein; Lung type I cell membrane associated glycoprotein T1A 2; OTS8; PA2.26; Pdpn; Podoplanin; PSEC0003; PSEC0025; T1-alpha; T1A; TI1A; TIA2
Angiogenesis, Dendritic Cell Marker, Endothelial Cell Marker
Showing all 7 results
Showing all 7 results
